Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD, Leading experts in relapsed/refractory multiple myeloma, explore evolving treatment landscapes, including CAR T-cell therapies, the role of selinexor, and optimized sequencing strategies, while addressing two complex clinical scenarios and providing key insights for community oncologists to enhance patient care.
Experts on adolescent and young adult acute lymphoblastic leukemia review patient cases have a comprehensive discussion on treatment practices and the evolving therapeutic landscape.
Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.
Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, examine the role of androgen receptor inhibitors, emphasize the significance of early intervention and biomarkers, and evaluate recent developments in the treatment paradigm for castration-sensitive prostate cancer.
A panel of experts on chronic lymphocytic leukemia review patient cases, discuss the latest research presented at ASCO 2024 and surrounding meetings, and provide insights on evolving clinical practices.
Martin H. Voss, MD, and Moshe Ornstein, MD, explore non-clear cell renal cell carcinoma and the potential impact of clinical trials on the evolution of treatment approaches.
Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the evolving landscape of HR+/HER2- metastatic breast cancer management, focusing on the clinical implications of ESR1 and PIK3CA mutations, the role of biomarker testing, the impact of novel therapies and combination strategies, and the importance of personalized treatment approaches in improving patient outcomes.
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, provide valuable insights into targeting the PI3K/AKT/PTEN pathway, exploring mechanisms of resistance, adverse event profiles, and treatment decision-making strategies for patients with HR+/HER2- locally advanced and metastatic breast cancer.
Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.
Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.
Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, provide comprehensive insights on the integration of hepatic artery infusion therapy into clinical practice for patients with colorectal cancer liver metastases and intrahepatic cholangiocarcinoma.
Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.
Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.
Funding supported by Taiho Oncology. Content independently developed by OncLive.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss the nuanced treatment landscape of myelofibrosis, exploring the latest advancements in JAK inhibitors, the importance of individualized care, and the potential of emerging combination therapies to enhance patient outcomes.
Hana Safah, MD, and Corey Cutler, MD, MPH, review recent data in graft-vs-host disease and provide comprehensive insights on treatment practices.
Shirish Gadgeel, MD, and Benjamin Levy, MD, discuss recent updates in 2023 on antibody-drug conjugates for treating patients with advanced NSCLC as well as their clinical implications.
Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, provide comprehensive insights on the evolving treatment landscape for patients with HR+ breast cancer and ESR1 mutations.
A panel of oncology specialists explores the latest developments in HER2-directed ADCs for solid tumors, emphasizing the growing potential in gynecological cancers.
Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements made in treatment approaches for NSCLC in 2023.
Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.
Expert medical oncologists Laura Spring, MD, and Manali Bhave, MD, discuss recent advances in the treatment of HER2-positive and HER2-low breast cancer, present hypothetical patient cases, and discuss their treatment approaches to illustrate how to incorporate recent data into practice.
Experts Joyce O’Shaughnessy, MD, and Erin Cobain, MD, review the clinical evolution of treatments in early-stage breast cancers, highlighting the latest data in genomic testing presented at the SABCS 2023 annual congress.
A panel of three, renowned oncologists discuss the evolving landscape of CAR-T cell therapies for adult patients with relapsed or refractory acute lymphoblastic leukemia after receiving two or more lines of prior therapy.
A group of oncology experts discusses the adjuvant treatment of melanoma, providing expert insights into the management of immunotherapy-related endocrine and cardiac toxicities, with a case discussion to emphasize these important topics.
Patient and provider perspectives are shared regarding available treatments, as well as how to manage treatment-related adverse events that can effect the quality of life for a patient diagnosed with cholangiocarcinoma.
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
A team of oncology experts discuss how collaboration among healthcare professionals can optimize care and improve quality of life for patients with advanced stage prostate cancer.
Neal Shore, MD, FACS, and Rana McKay, MD, discuss recent advances in understanding and targeting androgen receptor signaling in metastatic prostate cancer and emerging treatment approaches.
